Dicot moves forward with a new patent application
Uppsala, January 23, 2023. The pharmaceutical company Dicot AB that develops LIB-01 to become a new potency drug, today announces that it is moving forward with a new patent application. The patent application covers the new oral formulation for LIB-01 that was developed in 2022 and which will be used in the phase 1 clinical studies. This follows the IP strategy earlier communicated by the company.Dicot proceeds with one of its trade secrets and a new patent application based on this will be submitted to the Swedish Patent and Registration Office. It concerns the patenting of a way to